Publications by authors named "F P Worden"
Purpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. We reviewed our experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of palbociclib, a targeted cancer therapy, in patients with advanced cancer exhibiting specific genomic alterations, focusing on two patient groups: those with head and neck cancer (HNC) and those with a mix of histologies (HP).
- Results showed that 40% of the HNC patients achieved disease control, which was statistically significant, while only 13% of the HP cohort did, failing to meet the criteria for significance.
- The treatment had notable side effects, with over 40% of patients experiencing serious adverse events, primarily blood-related issues like neutropenia and thrombocytopenia.
Article Synopsis
- Squamoid eccrine ductal carcinoma is a rare tumor with characteristics that fall between squamous cell carcinoma (SCC) and certain sweat gland carcinomas, leading to debates on its classification.
- The study examined 15 cases of this carcinoma, revealing that most cases had UV signature mutations and TP53 mutations as the most common genetic alterations.
- Transcriptome analysis indicated that this carcinoma expresses 364 genes more and 525 genes less compared to SCC and sweat gland tumors, reinforcing the idea that it has an intermediate phenotype between these cancer types.
JCO LIBRETTO-001 is a registrational phase I/II, single-arm, open-label study of selpercatinib in patients with (REarranged during Transfection)-activated cancers (ClinicalTrials.gov identifier: NCT03157128). We present long-term safety and efficacy from LIBRETTO-001 in patients with -mutant medullary thyroid cancer (MTC; n = 324) and fusion-positive thyroid cancer encompassing different histological subtypes (TC; n = 66).
View Article and Find Full Text PDFArticle Synopsis
- This study investigates how specific quantitative measurements from SSTR-PET imaging and clinical biomarkers affect the progression-free survival (PFS) and overall survival (OS) of neuroendocrine tumor (NET) patients undergoing peptide receptor radionuclide therapy (PRRT).
- A total of 91 NET patients were analyzed, revealing that larger tumor volumes, especially in bones and the liver, correlate with shorter survival times, and that tumors with low SSTR uptake negatively impact patient outcomes.
- Elevated levels of the biomarkers chromogranin A and alkaline phosphatase were linked to worse survival, as well as a higher number of previous treatments and tumor origin, with midgut tumors associated with better PFS compared to pancreatic or unknown primary tumors.